SCHEMBL972325

SCHEMBL972325

CCOc1c[c]ccc1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
ESR1 P03372 1/20 0.38
TOP2A P11388 1/20 0.38
ABL1 P00519 1/20 0.37
ABCB1 P08183 1/20 0.37
BCR P11274 1/20 0.37
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
KDM4E B2RXH2 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
HPGD P15428 2/20 0.36
TSHR P16473 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
ALPI P09923 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27458021 0.85 MAPT (0.40) ALDH1A1MEN1KMT2AESR1KDM4E
SCHEMBL3043536 0.84 ALDH1A1 (0.40) ALDH1A1MEN1KMT2AESR1TOP2A
SCHEMBL27944106 0.83 ESR1 (0.43) ESR1TSHRGAAGLA
SCHEMBL127280 0.81 ALDH1A1 (0.39) ALDH1A1MEN1KMT2AKDM4EL3MBTL1
SCHEMBL929861 0.80 SMPD1 (0.47) ALDH1A1MEN1KMT2AESR1HPGD
SCHEMBL931517 0.80 SMPD1 (0.47) ALDH1A1MEN1KMT2AESR1HPGD
SCHEMBL10458094 0.79 ALDH1A1 (0.38) ALDH1A1MEN1KMT2AESR1KDM4E
SCHEMBL19924945 0.78 IDO1 (0.44) ALDH1A1GAA
SCHEMBL182716 0.77
SCHEMBL19925872 0.77 ESR1 (0.44) ALDH1A1ESR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 406 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113651843-A Bio-based toughening agent containing rigid-flexible structure and preparation method thereof 福建师范大学 2021-11-16 CN claimed
CN-108358841-B 4- ((2-substituted quinoline-4-yl) amino) benzoyl hydrazine derivatives, and preparation method and application thereof 厦门大学 2020-11-10 CN claimed
US-20190328690-A1 METHODS FOR TREATING C-MET-DEPENDENT CANCERS Board of Supervisors for the University of Louisiana System 2019-10-31 US claimed
US-10329249-B1 Sulindac derivatives KING SAUD UNIVERSITY (SA) 2019-06-25 US claimed
US-20190071416-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-03-07 US claimed
EP-3218458-B1 IMPROVMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2019-01-02 EP claimed
US-10119097-B2 Organic compounds GIVAUDAN S.A. (CH) 2018-11-06 US claimed
EP-3371151-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS Agency For Science, Technology And Research (SG) 2018-09-12 EP claimed
US-20170298292-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN S.A. (CH) 2017-10-19 US claimed
EP-3218458-A1 IMPROVMENTS IN OR RELATING TO ORGANIC COMPOUNDS Givaudan S.A. (CH) 2017-09-20 EP claimed
WO-2001021634-A1 BENZIMIDAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-03-29 WO claimed
EP-0740669-B1 AZATRIOXASPIROALKENES AS PARASITICIDES BAYER AG (DE) 1999-04-28 EP claimed
EP-0740669-A1 AZATRIOXASPIROALKENES AS PARASITICIDES BAYER AG (DE) 1996-11-06 EP claimed
WO-1995019364-A1 AZATRIOXASPIROALKENES AS PARASITICIDES BAYER AKTIENGESELLSCHAFT (DE) 1995-07-20 WO claimed
US-5321040-A Pesticidal 1-aryl-5-(substituted N-cinnamylideneimino) pyrazoles RHONE-POULENC INC. (US) 1994-06-14 US claimed
US-5236938-A Pesticidal 1-aryl-5-(substituted alkylideneimino)pyrazoles RHONE-POULENC INC. (US) 1993-08-17 US claimed
US-5231105-A Ethylamine derivatives and antihypertensives containing the same AJINOMOTO CO., INC. (JP) 1993-07-27 US claimed
EP-0511845-A1 Pesticidal 1-aryl-5-(substituted alkylideneimino)-pyrazoles RHONE-POULENC AGROCHIMIE (FR) 1992-11-04 EP claimed
US-5147463-A Organoleptic BASF K&F CORPORATION (US) 1992-09-15 US claimed
EP-0413162-A2 Novel cyclic acetals GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) 1991-02-20 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190071416-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS SMYD3, SMYD2, EHMT1 ALDH1A1 373/4885MEN1 1006/4885KMT2A 29/4885
US-10329249-B1 Sulindac derivatives SI, HRH2, SULT2A1 ALDH1A1 10/4885MEN1 4866/4885KMT2A 3389/4885
US-10119097-B2 Organic compounds OR10J3, CBR3, C9 ALDH1A1 1321/4885MEN1 4212/4885KMT2A 3388/4885
US-20190328690-A1 METHODS FOR TREATING C-MET-DEPENDENT CANCERS MET, VHL, MGMT ALDH1A1 1056/4885MEN1 53/4885KMT2A 644/4885
US-20170298292-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS OR10J3, C5, CBR3 ALDH1A1 1512/4885MEN1 4172/4885KMT2A 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.